BUSCADOR RECOLECTA

File "table1.dat" contains the CIG number, and general data for the total CO sample., File "tale4.dat" contains the CIG number, and the velocity integrated 12CO(1-0) intensities, line width and central velocities for galaxies newly observed., File "tale5.dat" contains the CIG number and the molecular gas mass for the total CO sample., We characterize the molecular gas content (ISM cold phase) using CO emission of a redshift-limited subsample of isolated galaxies from the AMIGA (Analysis of the interstellar Medium of Isolated GAlaxies) project in order to provide a comparison sample for studies of galaxies in different environments. We present the ^12^CO(1-0) data for 273 AMIGA galaxies, most of them (n=186) from our own observations with the IRAM 30m and the FCRAO 14m telescopes and the rest from the literature. We constructed a redshift-limited sample containing galaxies with 1500km/s

Table1: Galaxies from AMIGA sample listed as active in the literature, Table2: Radio-excess galaxies found using the radio-FIR correlation, Table4: Radio-excess galaxies in FIRST, Table5: Classified galaxies using the IRAS colour method, Table6: Catalogue of AGN-candidates for the total sample, This paper is part of a series involving the AMIGA project (Analysis of the Interstellar Medium of Isolated GAlaxies). This project provides a statistically-significant sample of the most isolated galaxies in the northern sky. We present a study of the nuclear activity in a well-defined sample of the most isolated galaxies (total sample: n=1050, complete subsample: n=719) in the local Universe traced by their far-infrared (FIR) and radio continuum emission. We use the well-known radio continuum-FIR correlation to select radio-excess galaxies that are candidates to host an active galactic nucleus (AGN), as well as the FIR colours to find obscured AGN-candidates. We also used the existing information on nuclear activity in the Veron-Cetty catalogue and in the NASA Extragalactic Database. A final catalogue of AGN-candidate galaxies has been produced that will provide a baseline for studies on the dependence of activity on the environment. Our sample is mostly radio quiet, consistent with its high content of late-type galaxies. At most ~1.5% of the galaxies show a radio excess with respect to the radio-FIR correlation, and this fraction even goes down to less than 0.8% after rejection of back/foreground sources using FIRST. We find that the fraction of FIR colour selected AGN-candidates is ~28% with a lower limit of ~7%. Our final catalogue contains 89 AGN candidates and is publicly available on the AMIGA web page (http://www.iaa.csic.es/AMIGA.html).

[Organism] Homo sapiens, [Experiment type] Expression profiling by array, [Overall design] Two-condition experiment, Progressing vs regressing metastases. 3 progressing and 2 regressing metastases extracted from the same patient after M-VAX immunotherapy. One replicate per array., [Platforms (1)] GPL7088 CCDTM Hs_CCDTM36k - version 1, [Relations] BioProject PRJNA130231, 1. Sample GSM592226. Title: melanoma progressing 1. Sample type: RNA. Platform ID: GPL7088. Series: GSE24067 Progressing vs regressing melanoma metastases; GSE26383 Response to immunotherapy in melanoma metastasis., Channel 1: [Source name] melanoma, progressing [Organism] Homo sapiens [Characteristics] tissue: melanoma treatment protocol: M-VAX preservation: cryopreservation patient: 1 [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy5 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., Channel 2: [Source name] Total RNA from pooled PBMC [Organism] Homo sapiens [Characteristics] tissue: Blood preservation: cryopreservation reference: Total RNA from pooled PBMC [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy3 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., [Hybridization protocol] 6 ug of labeled, fragmented cRNA per sample was applied to microarrays in Kreatech's Hybridization buffer, and hybridized for 16 h at 42C. After hybridization, slides were washed three four times with wash solutions containg gradually decreased concentrations of SSC (1x-0x) [Scan protocol] Scanned on an Agilent DNA Microarray Scanner. Images were quantified using Agilent Feature Extraction Software (version A.9.5.3). [Description] metastasis non responding after M-VAX immunotherapy 1 [Data processing] LOWESS normalized, background subtracted data obtained from log2 of processed Red signal/processed Green signal. Agilent software was used for feature extraction., 2. Sample GSM592227. Title: melanoma progressing 2. Sample type: RNA. Platform ID: GPL7088. Series (2): GSE24067 Progressing vs regressing melanoma metastases. GSE26383 Response to immunotherapy in melanoma metastasis., Channel 1 [Source name] melanoma, progressing [Organism] Homo sapiens [Characteristics] tissue: melanoma treatment protocol: M-VAX preservation: cryopreservation patient: 1 [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy5 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., Channel 2 [Source name] Total RNA from pooled PBMC [Organism] Homo sapiens [Characteristics] tissue: Blood preservation: cryopreservation reference: Total RNA from pooled PBMC [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy3 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., [Hybridization protocol] 6 ug of labeled, fragmented cRNA per sample was applied to microarrays in Kreatech's Hybridization buffer, and hybridized for 16 h at 42C. After hybridization, slides were washed three four times with wash solutions containg gradually decreased concentrations of SSC (1x-0x) [Scan protocol] Scanned on an Agilent DNA Microarray Scanner. Images were quantified using Agilent Feature Extraction Software (version A.9.5.3). [Description] metastasis non responding after M-VAX immunotherapy 2 [Data processing] LOWESS normalized, background subtracted data obtained from log2 of processed Red signal/processed Green signal. Agilent software was used for feature extraction., 3. Sample GSM592228. Title: melanoma progressing 3. Sample type: RNA. Platform ID: GPL7088. Series (2): GSE24067 Progressing vs regressing melanoma metastases; GSE26383 Response to immunotherapy in melanoma metastasis, Channel 1 [Source name] melanoma, progressing [Organism] Homo sapiens [Characteristics] tissue: melanoma treatment protocol: M-VAX preservation: cryopreservation patient: 1 [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy5 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., Channel 2 [Source name] Total RNA from pooled PBMC [Organism] Homo sapiens [Characteristics] tissue: Blood preservation: cryopreservation reference: Total RNA from pooled PBMC [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy3 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., [Hybridization protocol] 6 ug of labeled, fragmented cRNA per sample was applied to microarrays in Kreatech's Hybridization buffer, and hybridized for 16 h at 42C. After hybridization, slides were washed three four times with wash solutions containg gradually decreased concentrations of SSC (1x-0x) [Scan protocol] Scanned on an Agilent DNA Microarray Scanner. Images were quantified using Agilent Feature Extraction Software (version A.9.5.3). [Description] metastasis non responding after M-VAX immunotherapy 3 [Data processing] LOWESS normalized, background subtracted data obtained from log2 of processed Red signal/processed Green signal. Agilent software was used for feature extraction., 4. Sample GSM592229. Title: melanoma regressing 1. Sample type: RNA. Platform ID: GPL7088. Series (2): GSE24067 Progressing vs regressing melanoma metastases; GSE26383 Response to immunotherapy in melanoma metastasis., Channel 1 [Source name] melanoma, regressing [Organism] Homo sapiens [Characteristics] tissue: melanoma treatment protocol: M-VAX preservation: cryopreservation patient: 1 [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy5 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., Channel 2 [Source name] Total RNA from pooled PBMC [Organism] Homo sapiens [Characteristics] tissue: Blood preservation: cryopreservation reference: Total RNA from pooled PBMC [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy3 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., Hybridization protocol 6 ug of labeled, fragmented cRNA per sample was applied to microarrays in Kreatech's Hybridization buffer, and hybridized for 16 h at 42C. After hybridization, slides were washed three four times with wash solutions containg gradually decreased concentrations of SSC (1x-0x) [Scan protocol] Scanned on an Agilent DNA Microarray Scanner. Images were quantified using Agilent Feature Extraction Software (version A.9.5.3). [Description] metastasis responding after M-VAX immunotherapy 1 [Data processing] LOWESS normalized, background subtracted data obtained from log2 of processed Red signal/processed Green signal. Agilent software was used for feature extraction., 5. Sample GSM592230. Title: melanoma regressing 2. Sample type: RNA. Platform ID: GPL7088. Series (2): GSE24067 Progressing vs regressing melanoma metastases; GSE26383 Response to immunotherapy in melanoma metastasis., Channel 1 [Source name] melanoma, regressing [Organism] Homo sapiens [Characteristics] tissue: melanoma treatment protocol: M-VAX preservation: cryopreservation patient: 1 [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy5 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., Channel 2 [Source name] Total RNA from pooled PBMC [Organism] Homo sapiens [Characteristics] tissue: Blood preservation: cryopreservation reference: Total RNA from pooled PBMC [Extracted molecule] total RNA [Extraction protocol] Total RNA extracted using Qiagen's RNEasy Mini kit following manufacturer's instructions [Label] Cy3 [Label protocol] 0.5 µg of total RNA was primed with 0.25 ug oligo dT-T7 primer (5’ AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3’) at 70°C for 3 min, then reverse transcribed at 42°C for 90 min in the presence of 200 U SuperScript II RTase (Invitrogen), and 1 mM dNTP. Second strand synthesis was done with the 5’ primer switch method using 0.25 ug Ts/SMARTII primers (5’ AAG CAG TGG TAA CAA CGC AGA GTA CGC GGG 3’) for priming at 65°C for 1 min, and subsequent primer extension at 75°C for 30 min using the Advantage cDNA Polymerase Mix (Clontech) and 0.2mM dNTP. Double stranded cDNA subjected to in vitro transcription at 42°C for 6h using Megascript T7 kit (Ambion). After two rounds of linear amplification, cRNA was chemically labeled using ULS Cy3/Cy5 Fluorescent Labeling Kit (Kreatech), and fragmented by Fragmentation Reagents kit (Ambion)., [Hybridization protocol] 6 ug of labeled, fragmented cRNA per sample was applied to microarrays in Kreatech's Hybridization buffer, and hybridized for 16 h at 42C. After hybridization, slides were washed three four times with wash solutions containg gradually decreased concentrations of SSC (1x-0x) [Scan protocol] Scanned on an Agilent DNA Microarray Scanner. Images were quantified using Agilent Feature Extraction Software (version A.9.5.3). [Description] metastasis responding after M-VAX immunotherapy 2 [Data processing] LOWESS normalized, background subtracted data obtained from log2 of processed Red signal/processed Green signal. Agilent software was used for feature extraction., We documented the transcriptional pattern of 3 progressing and 2 regressing synchronous melanoma metastases from the same patient following M-VAX treatment.

[Organism] Rattus norvegicus, [Experiment type] Expression profiling by array, [Overall design] Breast tumors were induced with a single oral dosage of 7,12-dimethylbenz(alpha)anthracene (100 mg/kg body weight) in female Sprague-Dawley rats and subsequently treated with adriamycin (1 mg/kg body weight/week for 6 weeks) intravenously through lateral tail vein. Gene expression analysis was performed in paired samples as follows: ADR final trucut tumor vs initial trucut tumor (ADR final vs basal). For this assay, 5 samples were chosen according to histopathologic criteria (Bloom-Richardson grade II). Gene expression profiling was carried out using Affymetrix’s GeneChip technology, using the Rat Genome 230 2.0 array from this provider. All the protocols and apparatus were recommended by Affymetrix. Total RNA from frozen mammary tumors was extracted by RNeasy Mini kit and homogenized by QIAshredder columns according to manufacturer’s instructions. The quality and quantity of the obtained RNA was checked out through agarose electrophoresis and later spectrophotometry at 260/280 nm. Biotinylated cRNA was synthesized following the IVT labeling kit from Affymetrix and purified by the GeneChip Sample Cleanup Module from Affymetrix. The quality and quantity of the obtained cRNA was again checked out through agarose electrophoresis and posterior spectrophotometry at 260/280 nm. After hybridization, slides were washed and scanned following the manufacturer’s standard protocol. Intensity values were normalized by Robust Multichip Average method and subsequently these were filtered to remove the control sequences and those with a hybridization signal close to background. The spike controls were: BioB, BioC, BioD and Cre; because BioB was the least abundant in the samples, it was used to estimate the sensitivity of the experiment. The housekeeping control was GAPDH. After non-supervised clustering using Pearson correlation coefficient, statistical significance of gene expression was estimated by Student’s T test for paired samples, using GeneSpring GX 7.3 software (Agilent)., 1. GSM399913 Breast tumor biopsy_adriamycin_07SE125. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 09I1 (basal), 2. GSM399914 Total breast tumor_ adriamycin _07SE140. [Characteristics strain: ]Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 09I1 (final), 3. GSM399915 Breast tumor biopsy_adriamycin_07SE126. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 11D2 (basal), 4. GSM399916 Total breast tumor_ adriamycin _07SE141. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 11D2 (final), 5. GSM399949 Breast tumor biopsy_adriamycin_07SE127. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 12I1 (basal), 6. GSM399959 Total breast tumor_ adriamycin _07SE142. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 12I1 (final), 7. GSM399960 Breast tumor biopsy_adriamycin_07SE128. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 29I1 (basal), 8. GSM399961 Total breast tumor_ adriamycin _07SE143. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 29I1 (final), 9. GSM399980 Breast tumor biopsy_adriamycin_07SE129. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 43D1 (basal), 10. GSM399981 Total breast tumor_ adriamycin _07SE144. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 43D1 (final), The aim of this study was to compare the gene expression profile changes of DMBA-induced rat breast tumors after treatment with adriamycin. To this end, a cDNA microarray was performed (Affymetrix’s Rat Genome 230 2.0 array). This gene expression study was carried out on the tumor biopsy samples prior to adriamycin treatment, and compared with matched tumor biopsy samples after completion of the adriamycin treatment schedule.

In this dataset we show the total account of news for each university of Andalusia in Google News from 2011.

[Organism] Rattus norvegicus, [Experiment type] Expression profiling by array, [Overall design] Breast tumors were induced with a single oral dose of 7,12-dimethylbenz(alpha)anthracene (100 mg/kg body weight) in female Sprague-Dawley rats to test the antitumor power of orally administrated hydroxytyrosol (0.5 mg/kg body weight 5 days/week for 6 weeks). Gene expression analysis was performed in paired samples as follows: HT final trucut tumor vs initial trucut tumor (HT final vs basal). For this assay, 5 samples were chosen according to histopathologic criteria (Bloom-Richardson grade II). Gene expression profiling was carried out using Affymetrix’s GeneChip technology, using the Rat Genome 230 v2.0 array from this provider. All the protocols and apparatus were recommended by Affymetrix. Total RNA from frozen mammary tumors was extracted by RNeasy Mini kit and homogenized by QIAshredder columns according to manufacturer’s instructions. The quality and quantity of the obtained RNA was checked out through agarose electrophoresis and later spectrophotometry at 260/280 nm. Biotinylated cRNA was synthesized following the IVT labeling kit from Affymetrix and purified by the GeneChip Sample Cleanup Module from Affymetrix. The quality and quantity of the obtained cRNA was again checked out through agarose electrophoresis and posterior spectrophotometry at 260/280 nm. After hybridization, slides were washed and scanned following the manufacturer’s standard protocol. Intensity values were normalized by Robust Multichip Average method and subsequently these were filtered to remove the control sequences and those with a hybridization signal close to background. The spike controls were: BioB, BioC, BioD and Cre; because BioB was the least abundant in the samples, it was used to estimate the sensitivity of the experiment. The housekeeping control was GAPDH. After non-supervised clustering using Pearson correlation coefficient, statistical significance of gene expression was estimated by Student’s T test for paired samples using GeneSpring GX 7.3 software (Agilent)., [Platforms (1)] GPL1355 [Rat230_2] Affymetrix Rat Genome 230 2.0 Array, [Relations] BioProject PRJNA116997, 1. GSM399469 Breast tumor biopsy_hydroxytyrosol_07SE120. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 66D2 (basal), 2. GSM399474 Total breast tumor_hydroxytyrosol_07SE135. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 66D2 (final), 3. GSM399475 Breast tumor biopsy_hydroxytyrosol_07SE121. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 67D3(basal), 4. GSM399476 Total breast tumor_hydroxytyrosol_07SE136. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 67D3 (final), 5. GSM399477 Breast tumor biopsy_hydroxytyrosol_07SE122. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 45D3 (basal), 6. GSM399478 Total breast tumor_hydroxytyrosol_07SE137. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 45D3 (final), 7. GSM399892 Breast tumor biopsy_hydroxytyrosol_07SE123. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 49I1 (basal), 8. GSM399893 Total breast tumor_hydroxytyrosol_07SE138. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 49I1 (final), 9. GSM399894 Breast tumor biopsy_hydroxytyrosol_07SE124. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment . [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 51I1 (basal), 10. GSM399912 Total breast tumor_hydroxytyrosol_07SE139. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 51I1 (final), The aim of this study was to compare the gene expression profile changes of DMBA-induced rat breast tumors after treatment with hydroxytyrosol (a natural compound from virgin olive oil). To this end, a cDNA microarray experiment was performed (Affymetrix’s Rat Genome 230 2.0 array). This gene expression study was carried out on the tumor biopsy samples prior to hydroxytyrosol treatment, and compared with matched tumor biopsy samples after completion of the hydroxytyrosol treatment schedule. The result of this study was the identification of several genes related to apoptosis, cell cycle arrest, proliferation, differentiation, survival and transformation-related genes.

[Organism] Homo sapiens, [Experiment type] Expression profiling by array, [Overall design] Adipose tissue and blood samples were obtained from 27 children, 14 obese (BMI adjusted for age and sex z score > 2) and 13 non obese undergoing appendix surgery. About 400 mg of adipose tissue was taken and immediately immersed in RNAlater solution and stored at -80°C for gene expression analysis. Informed consent was obtained from all patients after the nature of the study was explained, and the experimental design was approved, from an ethical and scientific standpoint, by the Hospital’s Ethical Committee responsible for research., [Platforms (1)] GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array, [Relations] BioProject PRJNA103477, 1. GSM243215 Adipose tissue_423_control_rep1. [Source name] Omental adipose tissue, normal weight, child. [Characteristics] tissue: omental adipose group: normal weight gender: M age: 10 year z score bmi: -1.45, 2. GSM243216 Adipose tissue_425_control_rep2. [Source name] Omental adipose tissue, normal weight, child. [Characteristics] tissue: omental adipose group: normal weight gender: M age: 7 year z score bmi: 0.49, 3. GSM243217 Adipose tissue_426_control_rep3. [Source name] Omental adipose tissue, normal weight, child. [Characteristics] tissue: omental adipose group: normal weight gender: F age: 8 year z score bmi: 0.12, 4. GSM243218 Adipose tissue_427_control_rep4. [Source name] Omental adipose tissue, normal weight, child. [Characteristics] tissue: omental adipose group: normal weight gender: M age: 10 year z score bmi: -1.81, 5. GSM243219 Adipose tissue_428_control_rep5. [Source name] Omental adipose tissue, normal weight, child. [Characteristics] tissue: omental adipose group: normal weight gender: M age: 7 year z score bmi: -0.64, 6. GSM243220 Adipose tissue_429_control_rep6. [Source name] Omental adipose tissue, normal weight, child. [Characteristics] tissue: omental adipose group: normal weight gender: M age: 7 year z score bmi: -0.36, 7. GSM243225 Adipose tissue_418_obese_rep1. [Source name] Omental adipose tissue, obese, child. [Characteristics] tissue: omental adipose group: obese gender: M age: 11 years z score bmi: 2, 8. GSM243226 Adipose tissue_419_obese_rep2. [Source name] Omental adipose tissue, obese, child. [Characteristics] tissue: omental adipose group: obese gender: M age: 9 years z score bmi: 4.25, 9. GSM243227 Adipose tissue_420_obese_rep3. [Source name] Omental adipose tissue, obese, child. [Characteristics] tissue: omental adipose group: obese gender: M age: 12 years z score bmi: 2.36, 10. GSM243228 Adipose tissue_421_obese_rep4. [Source name] Omental adipose tissue, obese, child. [Characteristics] tissue: omental adipose group: obese gender: M age: 9 years z score bmi: 4.25, 11. GSM243275 Adipose tissue_422_obese_rep5. [Source name] Omental adipose tissue, obese, child. [Characteristics] tissue: omental adipose group: obese gender: M age: 10 years z score bmi: 2.72, Characterization of genes associated with adipose tissue is key to understanding the pathogenesis of obesity and developing treatments for this disorder. Differential gene expression in the adipose tissue has been described in adulthood but none studies have been developed on childhood. The purpose of this study was to compare gene expression in omental adipose tissue from obese prepubertal and normal weight children. We selected 5 obese (BMI adjusted for age and sex z score >2) and 6 normal weight children. RNA was extracted from omental adipose tissue biopsies and cRNA was hybridizated on the human genome U133 Plus 2.0 Arrays (Affymetrix®). Microarray experiments were performed for each sample, and selected group of gene expression values were confirmed with real-time RT-PCR in 10 obese and 10 normal weigth prepubertal children. 1276 genes were found to be differentially expressed at P<0.05. Of those differential genes, 201 were upregulated (Fc>2) and 42 were downregulated (Fc<-2). Genes involved in metabolic and signalling pathways were altered in childhood obesity. Keywords: disease state analysis

[Organism] Rattus norvegicus, [Experiment type] Expression profiling by array, [Overall design] Breast tumors were induced with a single oral dosage of 7,12-dimethylbenz(alpha)anthracene (100 mg/kg body weight) in female Sprague-Dawley rats. Gene expression analysis was performed in paired samples as follows: DMBA final trucut tumor vs initial trucut tumor (DMBA final vs basal). For this assay, 5 samples were chosen according to histopathologic criteria (Bloom-Richardson grade II). Gene expression profiling was carried out using Affymetrix’s GeneChip technology, using the Rat Genome 230 2.0 array from this provider. All the protocols and apparatus were recommended by Affymetrix. Total RNA from frozen mammary tumors was extracted by RNeasy Mini kit and homogenized by QIAshredder columns according to manufacturer’s instructions. The quality and quantity of the obtained RNA was checked out through agarose electrophoresis and later spectrophotometry at 260/280 nm. Biotinylated cRNA was synthesized following the IVT labeling kit from Affymetrix and purified by the GeneChip Sample Cleanup Module from Affymetrix. The quality and quantity of the obtained cRNA was again checked out through agarose electrophoresis and posterior spectrophotometry at 260/280 nm. After hybridization, slides were washed and scanned following the manufacturer’s standard protocol. Intensity values were normalized by Robust Multichip Average method and subsequently these were filtered to remove the control sequences and those with a hybridization signal close to background. The spike controls were: BioB, BioC, BioD and Cre; because BioB was the least abundant in the samples, it was used to estimate the sensitivity of the experiment. The housekeeping control was GAPDH. After non-supervised clustering using Pearson correlation coefficient, statistical significance of gene expression was estimated by Student’s T test for paired samples, using GeneSpring GX 7.3 software (Agilent)., [Platforms (1)] GPL1355 [Rat230_2] Affymetrix Rat Genome 230 2.0 Array, [Relations] BioProject PRJNA115167, 1. GSM398893 Breast tumor biopsy_DMBA_07SE115. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 31D3 (basal), 2. GSM398894 Total breast tumor_DMBA_07SE130. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 31D3 (final), 3. GSM399028 Breast tumor biopsy_DMBA_07SE116. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 32D1 (basal)., 4. GSM399030 Total breast tumor_DMBA_07SE131. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 32D1 (final), 5. GSM399430 Breast tumor biopsy_DMBA_07SE117. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 37I1 (basal), 6. GSM399433 Total breast tumor_DMBA_07SE132. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 37I1 (final), 7. GSM399434 Breast tumor biopsy_DMBA_07SE118. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 50I1 (basal), 8. GSM399456 Total breast tumor_DMBA_07SE133. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 50I1 (final), 9. GSM399460 Breast tumor biopsy_DMBA_07SE119. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 52I4 (basal), 10. GSM399466 Total breast tumor_DMBA_07SE134. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 52I4(final), The aim of this study was to compare the gene expression profile changes of DMBA-induced rat breast tumors from an initial stage to the moment of sacrifice. To this end, a cDNA microarray was performed (Affymetrix’s Rat Genome 230 2.0 array). This gene expression study was carried out on the umor biopsy samples and compared with matched tumor biopsy samples once the study ended (7 weeks after initial biopsy).

CSV file with scientific output of 102 countries (rows) by 27 major Scopus/SCImago subject areas, from 1996 to 2006. Data extracted from SCImago Journal & Country Rank (scimagojr.com).

[Organism] Rattus norvegicus, [Experiment type] Expression profiling by array, [Overall design] A single enema of 10mg of TNBS in 50% ethanol was administered to rats at day 0. Samples were recovered at days 2, 5, 7 and 14. According to inflammatory markers (myeloperoxidase activity, body weigh loss, colonic weigh/length ratio) we selected three replicates at each time point for the genimoc analysis, and 6 healthy control rats that received a saline enema. RNA was extracted from homogenized full-thickness colonic tissues in Trizol® reagent (Invitrogen) and purified with RNeasy affinity columns (Qiagen), according to manufacturer´s protocol. The microarray analysis was performed by Progenika Biopharma (Bilbao, Spain) on GeneChip® Rat Genome 230 2.0 Array (Affymetrix). All sample labeling (biotin), hybridization, staining and scanning procedures were carried out using Affimetrix, standard protocols (www.affymetrix.com). Normalization was carried out using Bioconductor sofware (affyPLM package)., [Platforms] GPL1355 [Rat230_2] Affymetrix Rat Genome 230 2.0 Array, [Relations] BioProject PRJNA102933, 1. GSM235052 Healthy control, replicate 1. [Characteristics] Sprague-Dawley female rats Tissue: full-thickness colon Rat received water, 2. GSM235053 Healthy control, replicate 2. Characteristics Sprague-Dawley female rats Tissue:full-thickness colon Rat received water, 3. GSM235055 Helathy control, replicate 3. [Characteristics] Sprague-Dawley female rats Tissue: full-thickness colon Rat received water, 4.GSM235056 Healthy control, replicate 4. [Characteristics] Sprague-Dawley female rats Tissue: full-thickness colon Rat received water, 5. GSM235057 Healthy control, replicate 5. [Characteristics] Sprague-Dawley female rats Tissue: full-thickness colon Rat received water, 6. GSM235058 Healthy control, replicate 6. [Characteristics] Sprague-Dawley female rats Tissue: full-thickness colon Rat received water, 7. GSM235552 TNBS day 2, replicate 1. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 8. GSM235558 TNBS day 2, replicate 2. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 9. GSM235559 TNBS day 2, replicate 3. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 10. GSM235643 TNBS day 5, replicate 1. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 11. GSM235745 TNBS day 5, replicate 2. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 12. GSM235832 TNBS day 5, replicate 3. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 13. GSM235872 TNBS day 7, replicate 1. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 14. GSM235873 TNBS day 7, replicate 2. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 15. GSM236126 TNBS day 7, replicate 3.[Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 16. GSM236922 TNBS day 14, replicate 1. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 17. GSM236924 TNBS day 14, replicate 2. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, 18. GSM236925 TNBS day 14, replicate 3. [Characteristics] Sprague-Dawley female rat Tissue: full-thickness colon Rat received an enema of 10mg TNBS in 50% ethanol at day 0, Trinitrobenzenesulfonic acid (TNBS) rat colitis is one of the most widely used models of inflammatory bowel disease, a condition whose etiology and pathophysiology are incompletely understood. We have characterized the model at the genomic level following a longitudinal approach.